I-Uloric (i-febuxostat) yavunywa yi-US FDA ngoFebruwari 13, 2009. I-Uloric yindlela yokuqala yokonyango olutsha kwiminyaka engama-40 kwizigulane ezine- hyperuricemia kunye ne-gout, ngokwe-Takeda Pharmaceuticals North America, Inc.
Uloric isilwanyana esisetyenziselwa ukuphathwa okungapheliyo kwe-hyperuricemia kwi-gout. I-Uloric iyanciphisa amanqanaba e-serum uric acid ngokuthintela i-xanthine oxidase-i-enyzme enoxanduva lokuveliswa kwe-uric acid.
I-Xanthine oxidase iphula i-hypoxanthine (i-purin derivative) eyenzeka ngokwemveli) kwi-xanthine, kwaye i-uric acid.
Ulawulwa njani iUloric?
Amanqanaba avunyelweyo a-Uloric anama-40 mg kunye no-80 mg ukuba anikwe kanye rhoqo. I-Uloric yonyango lomlomo (lithathwe ngomlomo). I-dolophu yokuqala yokucetyiswa ye-Uloric ingama 40 mg kanye ngosuku. Kunyuselwa kwizigulane ezingagqibekanga i-serum iric acid engaphantsi kwama-6 mg / dL emva kweveki ezimbini kwi-dose ye-40 mg. I-uloric ingathathwa kunye okanye ngaphandle kokutya kwaye akukho ziphakamiso zokuthintela ukusetyenziswa kwe-antacids. Akukho tshintsho lwedosa olufunekayo kwizigulane ezinomnxeba omncinci ukuya kumodareyitha okanye ukukhubazeka kwe-hepatic.
Ukusebenza kwiimvavanyo zeZliniki
Kwizilingo zekliniki, i-Uloric ephezulu ifunyenwe ukuba iphumelele kunokuba i-placebo okanye i-dose allopurinol efanelekileyo-enye iyeza esetyenziselwa ukunyanga i-hyperuricemia. Kwakhona, kwisilingo sesithathu seenyanga ezintathu-ipesenti yezigulane ze-gout, ezanciphisa amazinga azo e-uric kumazinga athile angaphantsi kwe-6, yayiphakamileyo kakhulu kulabo bathatha ama-80 mg kunokuba bathatha 40 mg ye-Uloric.
Iziphumo eziPhakathi kunye nezilumkiso
I-Uloric ayikhuthazwa ngabantu abane-hyperuricemia engabonakaliyo. I-uloric ayifanele isetyenziswe ngabantu abasele bephathwa nge- azathioprin (Imuran), mercaptopurine, ne-theophylline.
Ngokusekelwe kwizifundo ezintathu zokulawulwa kweengcali, ukunyanzelwa kwesibindi, ukugqithisa isibilini, i-arthralgia, kunye nokugqithiswa kwezidalwa ziyingozi eziqhelekileyo ezibangelwa ubuncinane kwi-1% yezigulane eziphathwe nge-Uloric kwaye ubuncinane ubuncinane be-0.5% ngaphezu kwe-placebo.
Kwakhona, xa kuthelekiswa ne-allopurinol, i-Uloric yayidibanise nesantya esiphezulu semicimbi ye-cardiovascular thromboembolic; Ukusebenza okungaqhelekanga kwimeko engafanelekileyo eyona nto ibonakalayo ekuthintela ukucinywa kwe-Uloric.
Kukho iingxelo zokumisa izimpawu zokungaphumeleli kwe-hepatic, ezibulalayo nabangenabungozi, kwizigulane eziphathwe nge-Uloric. Ezi ngxelo azizange zineenkcukacha ezaneleyo zokuseka isizathu nokuba kunjalo.
Ukunyuka kwe-gout flares kudlalwa ngamava xa ama-anti-hyperuricemic aqaliswa. Oku kuquka u-Uloric. Ukuba i-gout flare ehambelana nokuqaliswa kwonyango lwe-Uloric eyenzekayo, isilwanyana akuyidingi ukucinywa. Ukukhusela i-gout flares ehambelana nokuqaliswa kwonyango lwe-Uloric, i- NSAID okanye i-colchicin ingathathwa ngokufanayo. Ukunyuka kwe-gout flares kuye kwabanjelwa ukuhlahla kwamanqanaba e-serum uric acid, okwangoku kubangele ukuhamba kwe-urate kwi-tissue deposits.
Akukho zifundo ezilawulwa kakuhle ze-Uloric kwabasetyhini abakhulelweyo. Xa ukhulelwe, i-Uloric kufuneka isetyenziswe kuphela ukuba inzuzo ekulindelekileyo iphakamisa umngcipheko onokubakho kumntwana. Kwakhona, awaziwa ukuba i-Uloric ixutywe ebisi lomntu.
Abafazi abasweleyo mabaqaphele.
Ukhuseleko nokusebenza kwe-Uloric kubantwana abaneminyaka engaphantsi kwe-18 ubudala awaziwa.
Imithombo:
Ulwazi lwe-Uloric Prescribing Information. Uloric.com. Takeda Pharmaceuticals Inc. Ukuhlaziywa ngoMatshi 2013.
I-FDA Iyavuma i-ULORIC® (i-febuxostat) ye-Management Management ye-Hyperuricemia kwizigulane ezineGout. Takeda Pharmaceuticals. NgoFebruwari 13, 2009.